Document is current

Article History

Received: 4 June 2025

Accepted: 10 February 2026

First Online: 14 March 2026

Declarations

:

: Not applicable.

: Not applicable.

: OS reports consulting activities with Abdera, Actithera, AdvanCell, Alpha9, Amgen, ARTbio, Astellas, AstraZeneca, Bayer, Clarity Pharmaceuticals, Convergent, Curadh, Fusion, ITM Oncologics, Janssen (JNJ), Lantheus, Merck, Norroy, NorthStar, Novartis, Nucleus Biopharma, Pfizer, RATIO, Sanofi, Swiss Rockets, and Telix. He holds stock or options in Abdera, Actithera, AdvanCell, ArtBio, Clarity, Convergent, Ratio, and Telix. He has received clinical trial support to his institution from Amgen, AstraZeneca, Bayer, Janssen, and Novartis. FL discloses research funding and financial compensation from NaNotics LLC, a licensing agreement and royalties from Early is Good, and consulting for Mursla Bio. DSC reports honoraria, advisory board participation, or supported travel from Janssen (to institution), Novartis (to institution), Abdera (to institution), DAVA Oncology, Curio, Targeted Oncology, MJH Life Sciences, GU Oncology Now, IDEOlogy, IntrinsiQ, the American Society of Clinical Oncology, the Prostate Cancer Foundation, and the International Centers for Precision Oncology. He has received research funding from Janssen (to institution) and Novartis (to institution, in progress). ATK reports consulting for Novartis Inc. and research grant support to her institution from Novartis Inc. JJO receives research support from the Prostate Cancer Foundation (YIA), Department of Defense, and National Cancer Institute (K12 CA90628-23). JJO previously received research support from Nanotics, Genentech, and Partner Therapeutics. JJO reports support and/or research and consulting support from the Prostate Cancer Foundation, NaNotics, Genentech, and Partner Therapeutics. The other authors have no financial or non-financial conflicts of interest to declare.